Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2026, Elite Pharmaceuticals, Inc. reported revenue of $149M, up 77.1% year over year. Operating margin was 33.0% and net margin 30.1%, on a free-cash-flow margin of 15.3% with capital expenditure at 0.6% of revenue. Every figure is computed directly from ELTP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $149M | 33.0% | 30.1% |
| FY2025 | $84M | 23.3% | -5.1% |
| FY2024 | $57M | 19.1% | 35.5% |
| FY2023 | $34M | 10.8% | 10.4% |
| FY2022 | $32M | 15.7% | 27.6% |
How does ELTP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.